MAM
ECYT

Marquette Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Marquette Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-56,736
Closed -$80K – 80
2017
Q3 		$80K Buy
56,736
+18,563
+49% +$25.9K 0.03% 82
2017
Q2 		$57K Buy
+38,173
New +$82K 0.02% 86

Other funds holding ECYT

PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marquette Asset Management's ECYT Position: Q4 2017 in Review

Marquette Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2017, closing a stake of 56,736 shares — an estimated $80K sold.

Marquette Asset Management first reported a position in ECYT in Q2 2017 and held it in 2 quarters. The position peaked at $80K in Q3 2017. 71 funds tracked by Wall St. Rank hold ECYT as of Q4 2017.

  • Marquette Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Marquette Asset Management sold 56,736 Endocyte, Inc. Common Stock shares in Q4 2017, an estimated $80K.
  • Marquette Asset Management first reported a position in Endocyte, Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • Marquette Asset Management's Endocyte, Inc. Common Stock position peaked at $80K in Q3 2017.
  • 71 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2017.

Based on Marquette Asset Management's 13F filing for Q4 2017, filed 10 Jan 2018.